Novo Nordisk A/s Stock News

FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Dicerna Pharmaceuticals, Inc. Enters into a Definitive Agreement to be acquired by Novo Nordisk for USD3.3 Billion” Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA) surged over 78% in premarket trading after Novo Nordisk entered into a definitive agreement to acquire the company for roughly 3.3 billion… The post “The Buzz” Show: Dicerna Pharmaceuticals (NASDAQ: DRNA) Acquisition by Novo Nordisk first appeared on Financial Buzz .

Dicernas liver targeted GalXC technology uses liver-targeted GalXC-based compounds to enable subcutaneous delivery of RNAi therapies designed to specifically bind to receptors on liver cells, leading to internalization and access to the RNAi machinery within the cells. A next-generation version of GalXC, called GHalXC-Plus, extended Dicernas capabilities in RNAi silencing to address tissues and organs outside the liver, while retaining key pharmacological features from GalXC. The post From R&D to M&A: Novo Nordisk to Acquire Dicerna for $3.3B appeared first on GEN - Genetic Engineering and Biotechnology News .

Novo Nordisk paid $3.3 billion to acquire RNAi drug maker Dicerna Pharmaceuticals. Acquisition of Dicerna makes sense from a business standpoint as Novo's strength lies in the metabolic disorder space

WILMINGTON, Del., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Rigrodsky Law, P.A. announces that it is investigating Dicerna Pharmaceuticals, Inc. (Dicerna) (NASDAQ GS: DRNA ) regarding possible breaches of fiduciary duties and other violations of law related to Dicernas agreement to be acquired by Novo Nordisk A/S. Under the terms of the agreement, Dicernas shareholders will receive $38.25 in cash for each share of Dicerna common stock they own.

NEW YORK, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA) breached their fiduciary duties or violated the federal securities laws in connection with the companys acquisition by Novo Nordisk A/S (NYSE: NVO).

A juicy buyout offer from Novo Nordisk is giving Dicerna shareholders a big reason to cheer.

Wedbush Securities Inc. decreased its position in shares of Novo Nordisk A/S (NYSE:NVO) by 1.2% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 39,259 shares of the companys stock after selling 461 shares during the quarter. Wedbush Securities Inc.s holdings in Novo Nordisk []

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA) to Novo Nordisk for $38.25 per share in cash is fair to Dicerna shareholders. Halper Sadeh encourages Dicerna shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected]. The investigation concerns whether D

Dicerna Pharmaceuticals (DRNA) stock is surging higher on Thursday following news of a massive $3.3 billion deal with Novo Nordisk.

Novo Nordisk A/S (NYSE: NVO ) has agreed to acquire Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) for $38.25 per share in cash, representing a total equity value of $3.3 billion and a premium of 80% to Dicerna''s closing price on November 17, 2021. "The acquisition of Dicerna accelerates Novo Nordisk''s research within RNAi Full story available on Benzinga.com

Dicerna Pharmaceuticals (Nasdaq: DRNA) is a biopharma company that concentrates on developing RNAi therapeutics that announced that Novo Nordisk would acquire it for a total equity value of about $3.

Qurates most recent research report on Catheters, Needles, And Cannulas was performed by extremely qualified research professionals and business experts in order to provide an in-depth assessment on the market. The study on Catheters, Needles, And Cannulas is extensive and

https://www.investing.com/news/economy/denmarks-novo-nordisk-to-buy-dicerna-pharma-for-33-billion-2683932

Novo Nordisk said it''s buying Dicerna Pharmaceuticals for $3.3 billion, or $38.25 per share in cash. Dicerna ended Wednesday at $21.28. Novo Nordisk already had a research collaboration with Dicerna, and said the deal is part of a strategy of using a broad range of technology platforms applicable across all Novo Nordisk''s therapeutic focus areas. The existing collaboration between Novo Nordisk and Dicerna encompassed the exploration of more than 30 liver cell targets. Novo Nordisk said the deal will lead to an increase in research and development costs, with an estimated negative impact on operating profit growth in 2022 of around 3%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.